160 related articles for article (PubMed ID: 7554035)
21. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
23. ZD0473 pharmacokinetics in Japanese patients: a Phase I dose-escalation study.
Murakami H; Tamura T; Yamada Y; Yamamoto N; Ueda Y; Shimoyama T; Saijo N
Eur J Cancer; 2002 Dec; 38 Suppl 8():S1-5. PubMed ID: 12645906
[TBL] [Abstract][Full Text] [Related]
24. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).
Latif T; Wood L; Connell C; Smith DC; Vaughn D; Lebwohl D; Peereboom D
Invest New Drugs; 2005 Jan; 23(1):79-84. PubMed ID: 15528984
[TBL] [Abstract][Full Text] [Related]
26. An update on satraplatin: the first orally available platinum anticancer drug.
Kelland LR
Expert Opin Investig Drugs; 2000 Jun; 9(6):1373-82. PubMed ID: 11060749
[TBL] [Abstract][Full Text] [Related]
27. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.
Sessa C; Capri G; Gianni L; Peccatori F; Grasselli G; Bauer J; Zucchetti M; Viganò L; Gatti A; Minoia C; Liati P; Van den Bosch S; Bernareggi A; Camboni G; Marsoni S
Ann Oncol; 2000 Aug; 11(8):977-83. PubMed ID: 11038034
[TBL] [Abstract][Full Text] [Related]
28. [Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)].
Ota K; Wakui A; Majima H; Niitani H; Inuyama Y; Ogawa M; Ariyoshi Y; Yoshida O; Taguchi T; Kimura I
Gan To Kagaku Ryoho; 1992 Jun; 19(6):855-61. PubMed ID: 1605663
[TBL] [Abstract][Full Text] [Related]
29. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
Kim NK; Kim TY; Shin SG; Park YI; Lee JA; Cho YB; Kim KH; Kim DK; Heo DS; Bang YJ
Cancer; 2001 Apr; 91(8):1549-56. PubMed ID: 11301404
[TBL] [Abstract][Full Text] [Related]
30. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
Fokkema E; de Vries EG; Meijer S; Groen HJ
Cancer Chemother Pharmacol; 2000; 45(1):89-92. PubMed ID: 10647508
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
Mellish KJ; Kelland LR
Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
[TBL] [Abstract][Full Text] [Related]
32. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of cis-dichloro-trans-dihydroxy-bis(isopropylamine)platinum IV (CHIP).
Ribaud P; Gouveia J; Misset JL; Mathé G
Oncology; 1986; 43(2):78-82. PubMed ID: 3951788
[TBL] [Abstract][Full Text] [Related]
35. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
Raynaud FI; Odell DE; Kelland LR
Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.
Judson I; Cerny T; Epelbaum R; Dunlop D; Smyth J; Schaefer B; Roelvink M; Kaplan S; Hanauske A
Ann Oncol; 1997 Jun; 8(6):604-6. PubMed ID: 9261531
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S.
Ota K; Oguma T; Shimamura K
Anticancer Res; 1994; 14(3B):1383-7. PubMed ID: 8067710
[TBL] [Abstract][Full Text] [Related]
38. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV).
Sova P; Mistr A; Kroutil A; Semerád M; Chlubnová H; Hrusková V; Chládková J; Chládek J
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1247-56. PubMed ID: 20697713
[TBL] [Abstract][Full Text] [Related]
39. Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs.
Cermanova J; Chladek J; Soval P; Kroutil A; Semerad M; Berankova Z; Siroky P; Surova I
Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):679-85. PubMed ID: 15632953
[TBL] [Abstract][Full Text] [Related]
40. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]